Usa India 2020 Usa India

Aurobindo Pharma's Q4 earnings ahead of Street; launches key to future growth

Reading now: 767
www.livemint.com

Aurobindo Pharma Ltd’s March quarter results were a step ahead of the Street's expectations with revenues and profitability showing all-round improvement.

The steady Q4FY20 performance pushed its share price higher by about 3% on Thursday. Aurobindo’s revenue growth across geographies is encouraging, particularly from the overseas markets.

Its US formulations business clocked a steady growth of 21% year-on-year (YoY) in Q4. Europe formulations business also saw a decent increase of about 26% YoY.

The increase in anti-retroviral sales were a decent 31% y-o-y. Some of this could be attributed to pre-stocking though. Its Rest-of-the-World business stood at 30% YoY, which was even ahead of the US market.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA